KING OF PRUSSIA, Pa., Aug. 30, 2016 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for reviewthe company's Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks. HAE is a rare genetic disorder caused
"The review of this application is another step towards providing advanced prophylactic treatment options to people living with HAE," said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited. "Since CSL Behring first reported the possibility of C1-INH replacement therapy for HAE over 40 years ago, we have remained committed to innovative research and providing advanced treatment options to people living with HAE. Subcutaneous prophylaxis is the next important step in helping HAE patients to prevent HAE attacks."
About Hereditary Angioedema HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by lack of or malfunctioning C1-INH. As a result, there are inadequate amounts of properly functioning C1-INH, leading fluid to build up in body tissues, causing considerable swelling episodes referred to as angioedema. HAE attacks can affect many parts of the body and can spread to multiple sites, including the face, abdomen, larynx and extremities. Patients who have abdominal attacks of HAE can experience episodes of extreme pain, diarrhea, nausea and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if untreated, death.
About Subcutaneous C1 Esterase Inhibitor (C1-INH)C1 Esterase Inhibitor (Human) is an investigational, low-volume, subcutaneous prophylactic therapy. C1-INH replaces the missing or malfunctioning C1-INH protein in patients with a C1-INH deficiency, thereby preventing HAE attacks.
About CSL BehringCSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-accepts-csl-behrings-biologics-license-application-for-first-subcutaneous-prophylactic-therapy-to-prevent-hereditary-angioedema-attacks-300319903.html
SOURCE CSL Behring
Subscribe to our Free Newsletters!
Blood groups are of four important types determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All